ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
2 hedge funds and large institutions have $29K invested in ELITE PHARMACEUTICAL in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
61% more capital invested
Capital invested by funds: $18K → $29K (+$11K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFAG
Blackston Financial Advisory Group
The Villages,
Florida
|
+$10.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFAG
1
Blackston Financial Advisory Group
The Villages,
Florida
| $25K | +$10.3K | +238,290 | +70% |
|
2
Fisher Asset Management
Camas,
Washington
| $4K | – | – | – |
|
ELI Hedge Fund Activity: Q2 2022 in Review
2 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2022, worth a combined $29K — up 61% from $18K a quarter earlier.
Fund positioning in ELI was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Blackston Financial Advisory Group, adding an estimated $10.3K.
- 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $29K of ELITE PHARMACEUTICAL stock for Q2 2022, up 61% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2022 and 0 closed out.
- The largest ELITE PHARMACEUTICAL buyer in Q2 2022 was Blackston Financial Advisory Group, an estimated $10.3K added.
Based on aggregated 13F filings for Q2 2022.